Recent Updates
Recently added Catalysts

Allogeneic Cardiosphere-Derived Cells

Phase 2

Duchenne Muscular Dystrophy | Small molecule | Neurology |Capricor Therapeutics, Inc.|Last Updated: Jan 8, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials2
Total Enrollment33
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06304064Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)PHASE2 COMPLETED 8 — — Jun 1, 2018Mar 1, 2019Apr 23, 2024 - —
NCT02485938HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)PHASE2 COMPLETED 25 — — Jan 1, 2016Sep 1, 2017Jan 8, 2025 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
Allogeneic Cardiosphere-Derived Cells (CAP-1002)BIOLOGICALIntravenous infusion delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002; 75 million CDCs)
Unlock Study Design Details